Perceptive Advisors - Q1 2021 holdings

$7.91 Billion is the total value of Perceptive Advisors's 139 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 200.0% .

 Value Shares↓ Weighting
BBIO BuyBRIDGEBIO PHARMA INC$477,827,000
+0.2%
7,756,928
+15.7%
6.04%
+18.1%
SWTX BuySPRINGWORKS THERAPEUTICS INC$356,808,000
+17.8%
4,849,912
+16.1%
4.51%
+38.8%
BIIB NewBIOGEN INCcall$209,253,000748,000
+100.0%
2.65%
BIIB NewBIOGEN INCput$167,850,000600,000
+100.0%
2.12%
LABP NewLANDOS BIOPHARMA INC$140,967,00014,869,915
+100.0%
1.78%
ZYME BuyZYMEWORKS INC$136,769,000
-32.7%
4,330,868
+0.7%
1.73%
-20.7%
ALDX BuyALDEYRA THERAPEUTICS INC$103,402,000
+139.8%
8,703,879
+38.5%
1.31%
+182.5%
SLDB BuySOLID BIOSCIENCES INC$74,171,000
-9.4%
13,412,552
+24.1%
0.94%
+6.7%
CHRS BuyCOHERUS BIOSCIENCES INC$68,632,000
-15.5%
4,697,612
+0.6%
0.87%
-0.3%
MGNX BuyMACROGENICS INC$68,416,000
+137.3%
2,148,060
+70.3%
0.86%
+179.9%
CERE BuyCEREVEL THERAPEUTICS HLDNG I$63,749,000
-15.4%
4,643,095
+2.2%
0.81%
-0.4%
ATHA BuyATHIRA PHARMA INC$63,037,000
-40.9%
3,425,916
+10.0%
0.80%
-30.4%
ESTA BuyESTABLISHMENT LABS HLDGS INC$61,735,000
+135.4%
987,287
+41.7%
0.78%
+177.9%
MORF BuyMORPHIC HLDG INC$59,365,000
+263.3%
938,140
+92.6%
0.75%
+329.1%
RXDX NewPROMETHEUS BIOSCIENCES INC$55,354,0003,314,032
+100.0%
0.70%
RAPT BuyRAPT THERAPEUTICS INC$55,000,000
+76.5%
2,477,481
+57.1%
0.70%
+108.4%
VRCA BuyVERRICA PHARMACEUTICALS INC$54,698,000
+39.3%
3,610,412
+5.9%
0.69%
+64.4%
VERU BuyVERU INC$47,963,000
+70.6%
4,451,342
+37.0%
0.61%
+101.0%
EXAS NewEXACT SCIENCES CORP$46,587,000353,523
+100.0%
0.59%
VYNE NewVYNE THERAPEUTICS INC$46,368,0006,773,954
+100.0%
0.59%
DBVT BuyDBV TECHNOLOGIES S Asponsored adr$41,017,000
+137.4%
7,695,505
+16.7%
0.52%
+180.5%
BEAM NewBEAM THERAPEUTICS INC$37,832,000537,635
+100.0%
0.48%
ACAD NewACADIA PHARMACEUTICALS INC$36,386,0001,410,305
+100.0%
0.46%
UTHR NewUNITED THERAPEUTICS CORP DEL$29,272,000175,000
+100.0%
0.37%
NUVB NewNUVATION BIO INC$29,041,0003,041,004
+100.0%
0.37%
ISEE BuyIVERIC BIO INC$28,338,000
-8.5%
4,585,512
+2.3%
0.36%
+7.8%
ATEC NewALPHATEC HOLDINGS INC$25,490,0001,800,180
+100.0%
0.32%
HCAT BuyHEALTH CATALYST INC$23,670,000
+97.0%
506,084
+83.3%
0.30%
+131.8%
FBRX BuyFORTE BIOSCIENCES INC$23,475,000
+84.2%
685,000
+95.7%
0.30%
+116.8%
MREO NewMEREO BIOPHARMA GROUP PLCads$20,220,0006,000,000
+100.0%
0.26%
IMCR NewIMMUNOCORE HLDGS PLCads$17,028,000400,000
+100.0%
0.22%
ACRS NewACLARIS THERAPEUTICS INC$16,380,000650,000
+100.0%
0.21%
CMIIU NewCM LIFE SCIENCES II INCunit 02/25/2028$16,000,0001,250,000
+100.0%
0.20%
HCAQ NewHEALTHCOR CATALIO ACQU CORPcl a shrs$14,880,0001,500,000
+100.0%
0.19%
ACHL NewACHILLES THERAPEUTICS PLCsponsored ads$12,501,000755,375
+100.0%
0.16%
CLOV NewCLOVER HEALTH INVESTMENTS CO$10,322,0001,500,000
+100.0%
0.13%
RACB NewRESEARCH ALLIANCE CORP II$10,250,0001,000,000
+100.0%
0.13%
XENE NewXENON PHARMACEUTICALS INC$9,219,000515,042
+100.0%
0.12%
FGEN NewFIBROGEN INCput$6,942,000200,000
+100.0%
0.09%
NewDARIOHEALTH CORP$6,314,000327,869
+100.0%
0.08%
NewCATABASIS PHARMACEUTICALS IN$5,588,0001,933,551
+100.0%
0.07%
LGVU NewLONGVIEW ACQUISITION CORP IIunit 99/99/9999$5,020,000500,000
+100.0%
0.06%
TXMD NewTHERAPEUTICSMD INC$3,685,0002,750,000
+100.0%
0.05%
MRUS NewMERUS N V$3,655,000175,000
+100.0%
0.05%
TLIS NewTALIS BIOMEDICAL CORP$3,212,000250,000
+100.0%
0.04%
RGNX NewREGENXBIO INC$2,363,00069,283
+100.0%
0.03%
PLXP NewPLX PHARMA INC$2,006,000222,180
+100.0%
0.02%
CMLF NewCM LIFE SCIENCES INC$1,891,000127,000
+100.0%
0.02%
BFLYWS NewBUTTERFLY NETWORK INC*w exp 05/27/202$1,505,000233,333
+100.0%
0.02%
SCPEWS NewSC HEALTH CORP*w exp 99/99/999$945,000500,000
+100.0%
0.01%
PHVS NewPHARVARIS N V$755,00027,000
+100.0%
0.01%
CEREW NewCEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202$573,000133,066
+100.0%
0.01%
CVM NewCEL-SCI CORP$513,00033,700
+100.0%
0.01%
SANA NewSANA BIOTECHNOLOGY INC$335,00010,000
+100.0%
0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2021-08-13
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q1 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings